Drugs / Goflikicept

Trials 12 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07206043 Dec 2024 → Feb 2025 R-Pharm International, LLC Completed No outcome recorded
Phase 25 trials
Phase 2 NCT04213274 May → Aug 2023 Schnitzler syndrome R-Pharm Overseas, Inc. Withdrawn No outcome recorded
Phase 2 NCT05190991 Oct 2021 → Dec 2028 expected familial Mediterranean fever R-Pharm International, LLC Recruiting No outcome recorded
Phase 2 NCT05092776 Apr 2021 → Jan 2025 overdue familial Mediterranean fever R-Pharm International, LLC Active not recruiting No outcome recorded
Phase 2 NCT04463251 Dec 2020 → Nov 2021 ST-elevation myocardial infarction R-Pharm Overseas, Inc. Completed No outcome recorded
Phase 2 NCT04067492 Mar 2018 → Mar 2020 gout R-Pharm Terminated No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT05107934 Dec 2025 → May 2027 pericarditis R-Pharm Overseas, Inc. Suspended No outcome recorded
Phase 2/3 NCT04380519 Apr → Jul 2020 COVID-19 R-Pharm International, LLC Completed No outcome recorded
Phase 2/3 NCT04692766 Feb 2020 → Jan 2022 idiopathic recurrent pericarditis R-Pharm International, LLC Completed No outcome recorded
Phase 33 trials
Phase 3 NCT07625384 May 2026 → Dec 2027 expected R-Pharm International, LLC Not yet recruiting No outcome recorded
Phase 3 NCT05432960 Dec 2023 → Aug 2025 adult-onset Still disease R-Pharm International, LLC Withdrawn No outcome recorded
Phase 3 NCT05673902 Dec 2020 → Jan 2026 overdue idiopathic recurrent pericarditis R-Pharm International, LLC Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02667639 Comparator Jan 2016 → Jun 2017 R-Pharm Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as Goflikicept ClinicalTrials.gov intervention name — accepted as the source's own label NCT07625384
Known as GFC “The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease” NCT07625384
Known as L04018 “RPH-104 (RPH-104/L04018) Administered at Different Doses” NCT04067492
Known as RPH-104 “single dose of RPH-104 in adult patients with acute gout attack” NCT04067492
11

NCT07206043

NCT05107934

NCT04380519

NCT04213274

NCT04463251

NCT05190991

NCT05432960

NCT04692766

NCT05092776

NCT05673902

NCT02667639

Action Inhibit “a highly potent inhibitor of IL-1β signalling pathway” NCT02667639
Modality Monoclonal antibody “Anti-IL-1 Mab” NCT02667639
Route Subcutaneous “A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.” NCT02667639